La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Behavioural effects of genetically engineered cells releasing dopa and dopamine after intracerebral grafting in a rat model of Parkinson's disease.

Identifieur interne : 000634 ( Ncbi/Checkpoint ); précédent : 000633; suivant : 000635

Behavioural effects of genetically engineered cells releasing dopa and dopamine after intracerebral grafting in a rat model of Parkinson's disease.

Auteurs : P. Horellou [France] ; C. Lundberg ; B. Le Bourdellès ; K. Wictorin ; P. Brundin ; P. Kalén ; A. Björklund ; J. Mallet

Source :

RBID : pubmed:1687823

English descriptors

Abstract

The relative importance of synaptic versus paracrine dopamine transmission for the occurrence of functional effects following intrastriatal grafting is not fully established. In the present study we grafted cell lines, expressing the form I of human tyrosine hydroxylase after infection with a recombinant retrovirus and selection in tyrosine-free-medium, to the denervated striatum in order to analyse the extent to which extracellular dopamine levels can be restored and the effect of a diffuse release of dopamine on motor impairement in a rat model of Parkinson's disease. In petri dish, the modified fibroblast cells (NIH.3T3) release DOPA constitutively whereas the modified endocrine cells (RIN) store and release dopamine in a regulated way. Interestingly, in denervated striatum, grafts of modified fibroblast cells produce DOPA which was efficiently converted into dopamine by the host striatal tissue. In the grafted striatum, both fibroblast and endocrine cells restore subnormal levels of diffuse release of dopamine which is notably unaffected and stimulated, respectively, by high concentration of potassium, in connection with the in vitro properties of the grafted cells. The intrastriatal grafts of modified cells partially reversed the apomorphine-induced but not the amphetamine-induced motor asymmetry. We discuss the implications of these results in the context of Parkinson disease.

PubMed: 1687823


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:1687823

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Behavioural effects of genetically engineered cells releasing dopa and dopamine after intracerebral grafting in a rat model of Parkinson's disease.</title>
<author>
<name sortKey="Horellou, P" sort="Horellou, P" uniqKey="Horellou P" first="P" last="Horellou">P. Horellou</name>
<affiliation wicri:level="3">
<nlm:affiliation>LNBCM, CNRS, Gif-sur-Yvette, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>LNBCM, CNRS, Gif-sur-Yvette</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Gif-sur-Yvette</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lundberg, C" sort="Lundberg, C" uniqKey="Lundberg C" first="C" last="Lundberg">C. Lundberg</name>
</author>
<author>
<name sortKey="Le Bourdelles, B" sort="Le Bourdelles, B" uniqKey="Le Bourdelles B" first="B" last="Le Bourdellès">B. Le Bourdellès</name>
</author>
<author>
<name sortKey="Wictorin, K" sort="Wictorin, K" uniqKey="Wictorin K" first="K" last="Wictorin">K. Wictorin</name>
</author>
<author>
<name sortKey="Brundin, P" sort="Brundin, P" uniqKey="Brundin P" first="P" last="Brundin">P. Brundin</name>
</author>
<author>
<name sortKey="Kalen, P" sort="Kalen, P" uniqKey="Kalen P" first="P" last="Kalén">P. Kalén</name>
</author>
<author>
<name sortKey="Bjorklund, A" sort="Bjorklund, A" uniqKey="Bjorklund A" first="A" last="Björklund">A. Björklund</name>
</author>
<author>
<name sortKey="Mallet, J" sort="Mallet, J" uniqKey="Mallet J" first="J" last="Mallet">J. Mallet</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1991">1991</date>
<idno type="RBID">pubmed:1687823</idno>
<idno type="pmid">1687823</idno>
<idno type="wicri:Area/PubMed/Corpus">001809</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001809</idno>
<idno type="wicri:Area/PubMed/Curation">001768</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001768</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001768</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001768</idno>
<idno type="wicri:Area/Ncbi/Merge">000634</idno>
<idno type="wicri:Area/Ncbi/Curation">000634</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000634</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Behavioural effects of genetically engineered cells releasing dopa and dopamine after intracerebral grafting in a rat model of Parkinson's disease.</title>
<author>
<name sortKey="Horellou, P" sort="Horellou, P" uniqKey="Horellou P" first="P" last="Horellou">P. Horellou</name>
<affiliation wicri:level="3">
<nlm:affiliation>LNBCM, CNRS, Gif-sur-Yvette, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>LNBCM, CNRS, Gif-sur-Yvette</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Gif-sur-Yvette</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lundberg, C" sort="Lundberg, C" uniqKey="Lundberg C" first="C" last="Lundberg">C. Lundberg</name>
</author>
<author>
<name sortKey="Le Bourdelles, B" sort="Le Bourdelles, B" uniqKey="Le Bourdelles B" first="B" last="Le Bourdellès">B. Le Bourdellès</name>
</author>
<author>
<name sortKey="Wictorin, K" sort="Wictorin, K" uniqKey="Wictorin K" first="K" last="Wictorin">K. Wictorin</name>
</author>
<author>
<name sortKey="Brundin, P" sort="Brundin, P" uniqKey="Brundin P" first="P" last="Brundin">P. Brundin</name>
</author>
<author>
<name sortKey="Kalen, P" sort="Kalen, P" uniqKey="Kalen P" first="P" last="Kalén">P. Kalén</name>
</author>
<author>
<name sortKey="Bjorklund, A" sort="Bjorklund, A" uniqKey="Bjorklund A" first="A" last="Björklund">A. Björklund</name>
</author>
<author>
<name sortKey="Mallet, J" sort="Mallet, J" uniqKey="Mallet J" first="J" last="Mallet">J. Mallet</name>
</author>
</analytic>
<series>
<title level="j">Journal de physiologie</title>
<idno type="ISSN">0021-7948</idno>
<imprint>
<date when="1991" type="published">1991</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Catechols (metabolism)</term>
<term>Corpus Striatum (metabolism)</term>
<term>Corpus Striatum (transplantation)</term>
<term>Dihydroxyphenylalanine (pharmacokinetics)</term>
<term>Dihydroxyphenylalanine (pharmacology)</term>
<term>Disease Models, Animal</term>
<term>Dopamine (pharmacokinetics)</term>
<term>Dopamine (pharmacology)</term>
<term>Genetic Engineering</term>
<term>Motor Activity (drug effects)</term>
<term>Parkinson Disease (genetics)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (surgery)</term>
<term>Rats</term>
<term>Tyrosine 3-Monooxygenase (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Catechols</term>
<term>Tyrosine 3-Monooxygenase</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Motor Activity</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Corpus Striatum</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en">
<term>Dihydroxyphenylalanine</term>
<term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Dihydroxyphenylalanine</term>
<term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="transplantation" xml:lang="en">
<term>Corpus Striatum</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Disease Models, Animal</term>
<term>Genetic Engineering</term>
<term>Rats</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The relative importance of synaptic versus paracrine dopamine transmission for the occurrence of functional effects following intrastriatal grafting is not fully established. In the present study we grafted cell lines, expressing the form I of human tyrosine hydroxylase after infection with a recombinant retrovirus and selection in tyrosine-free-medium, to the denervated striatum in order to analyse the extent to which extracellular dopamine levels can be restored and the effect of a diffuse release of dopamine on motor impairement in a rat model of Parkinson's disease. In petri dish, the modified fibroblast cells (NIH.3T3) release DOPA constitutively whereas the modified endocrine cells (RIN) store and release dopamine in a regulated way. Interestingly, in denervated striatum, grafts of modified fibroblast cells produce DOPA which was efficiently converted into dopamine by the host striatal tissue. In the grafted striatum, both fibroblast and endocrine cells restore subnormal levels of diffuse release of dopamine which is notably unaffected and stimulated, respectively, by high concentration of potassium, in connection with the in vitro properties of the grafted cells. The intrastriatal grafts of modified cells partially reversed the apomorphine-induced but not the amphetamine-induced motor asymmetry. We discuss the implications of these results in the context of Parkinson disease.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>France</li>
</country>
<region>
<li>Île-de-France</li>
</region>
<settlement>
<li>Gif-sur-Yvette</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Bjorklund, A" sort="Bjorklund, A" uniqKey="Bjorklund A" first="A" last="Björklund">A. Björklund</name>
<name sortKey="Brundin, P" sort="Brundin, P" uniqKey="Brundin P" first="P" last="Brundin">P. Brundin</name>
<name sortKey="Kalen, P" sort="Kalen, P" uniqKey="Kalen P" first="P" last="Kalén">P. Kalén</name>
<name sortKey="Le Bourdelles, B" sort="Le Bourdelles, B" uniqKey="Le Bourdelles B" first="B" last="Le Bourdellès">B. Le Bourdellès</name>
<name sortKey="Lundberg, C" sort="Lundberg, C" uniqKey="Lundberg C" first="C" last="Lundberg">C. Lundberg</name>
<name sortKey="Mallet, J" sort="Mallet, J" uniqKey="Mallet J" first="J" last="Mallet">J. Mallet</name>
<name sortKey="Wictorin, K" sort="Wictorin, K" uniqKey="Wictorin K" first="K" last="Wictorin">K. Wictorin</name>
</noCountry>
<country name="France">
<region name="Île-de-France">
<name sortKey="Horellou, P" sort="Horellou, P" uniqKey="Horellou P" first="P" last="Horellou">P. Horellou</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000634 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000634 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:1687823
   |texte=   Behavioural effects of genetically engineered cells releasing dopa and dopamine after intracerebral grafting in a rat model of Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i   -Sk "pubmed:1687823" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024